Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia

Main Article Content

Omar Salad Elmi
Habsah Hasan
Sarimah Abdullah
Mat Zuki Mat Jeab
Zilfalil Ba
Nyi Nyi Naing

Abstract

Background: Treating patients with multidrug-resistant tuberculosis (MDR-TB) strains is more complicated, complex, toxic, expensive, than treating patients with susceptible TB strains. This study aims to compare the treatment outcomes and potential factors associated between patients with MDR-TB and non MDR TB infections in peninsular Malaysia. Methods: This study was a retrospective cohort study. Data were collected from the medical records of all registered MDR-TB patients and Non-MDR-TB patients at five TB hospitals in peninsular Malaysia from January 2010 to January 2014. Results: A total of 314 subjects were studied, including 105 MDR-TB cases and 209 non-MDRTB. After TB treatment, 24.8% of the MDR-TB patients and 17.7% of non MDR TB relapsed; 17.1% of the MDR-TB patients and 16.3% of non MDR TB defaulted from TB treatment. A significant difference seen in treatment success rate 17.1% for MDR-TB; 63.1% for non MDR TB (P < 0.001)). Mortality rate were 8.9% for MDR-TB; 13.2% for non MDR TB. Multivariable analysis showed the potential factors associated with poor treatment outcomes were presence of HIV infection (AOR, 1.09; 95%CI: 1.05, 1.75; P = 0.001) and previous TB treatment (AOR, 4.87; 95%CI: 2.84, 8.38; P = 0.001). Conclusion: This study revealed that the treatment success rate in patients with non MDR TB infection was higher than MDR-TB. Unsuccessful treatment was seen in MDR-TB associated with potential factors such as history of TB treatment, and presence of HIV infection.

Article Details

Section

Original Articles

How to Cite

1.
Omar Salad Elmi, Habsah Hasan, Sarimah Abdullah, Mat Zuki Mat Jeab, Zilfalil Ba, Nyi Nyi Naing. Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia. Malays J Med Sci [Internet]. 2016 Jun. 30 [cited 2026 Nov. 11];23(4):17–25. Available from: https://ejournal.usm.my/mjms/article/view/mjms_vol23-no4-2016_3

References

Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003; 362:887–899. http://dx.doi.org/10.1016/S0140-6736(03)14333-4

Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006; 368:2142–2154. http://dx.doi.org/10.1016/S0140-6736(06)69863-2

Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368:1575–1580. http://dx.doi.org/10.1016/S0140-6736(06)69573-1

Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrugresistant tuberculosis. J Infect Dis. 2006; 194:479–485. http://dx.doi.org/10.1086/505877

Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova O, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Resir J. 2007; 30:623–626. http://dx.doi.org/10.1183/09031936.00077307

Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, et al. Treatment outcomes and longterm survival in patients with extensively drugresistant tuberculosis. Am J Respir Crit Care Med. 2008:178:1075–1082. http://dx.doi.org/10.1164/rccm.200801-132OC

Udwadia ZF. XDR-TB in India: when will we heed the alarm? J Assoc Physicians India.2008; 56:409–410.

Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: review. Curr Opin Infect Dis. 2008; 21:587–595. http://dx.doi.org/10.1097/QCO.0b013e328319bce6

Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993; 328:527–532. http://dx.doi.org/10.1056/NEJM199302253280802

Extensively drug-resistant tuberculosis—United States, 1993-2006.Morbidity and Mortality Weekly Report. 2007; 56:250–253.

World Health Organisation (WHO). WHO report: Global tuberculosis control 2011. Geneva: WHO; 2011.

Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with MDR TB in KwaZulu-Natal, South Africa, 2000–2003. Int J Tuberc Lung Dis. 2010; 14:413.

Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis. 2008; 198:1582–1589. http://dx.doi.org/10.1086/592991

Canetti G, Rist N, Grosset J. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation [Article in French]. Rev Tuberc Pneumol (Paris). 1963; 27:217–272.

Agresti A. Building and applying logistic regression models. In Categorical Data Analysis, Second Edition. Hoboken, NJ: John Wiley & Sons; 211–266: 2002. http://dx.doi.org/10.1002/0471249688.ch6

WHO. WHO report: Tuberculosis profile report in Malaysia. Geneva: WHO; 2011 and 2012.

Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007; 45:1290–1295. http://dx.doi.org/10.1086/522537

Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007; 30:623–626. http://dx.doi.org/10.1183/09031936.00077307

Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986; 133:423–430.

Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis. 1997; 24:S121–S130. http://dx.doi.org/10.1093/clinids/24.Supplement_1.S121

21. Dooley SW, Jarvis WR, Marione WJ, Snider DE, Jr. Multidrug-resistant tuberculosis. Ann Inter Med. 1992; 117(3):257–259. http://dx.doi.org/10.7326/0003-4819-117-3-257

Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. J AM Med Assoc.1993; 270:65–68. http://dx.doi.org/10.1001/jama.1993.03510010071032

Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008; 178(10):1075– 1082. http://dx.doi.org/10.1164/rccm.200801-132OC

Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, et al. Outcome of pulmonary multidrugresistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006; 28:980–985. http://dx.doi.org/10.1183/09031936.06.00125705

Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372:1403–1409. http://dx.doi.org/10.1016/S0140-6736(08)61204-0

Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008; 12:1182–1189.

Palmero D, Ambroggi M, Brea A, De Lucas M, Fulgenzi A, Martínez D, et al. Treatment an followup of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis. 2004: 8(6):778–784.

Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003; 348:119–128. http://dx.doi.org/10.1056/NEJMoa022928

Escudero E, Pena J, Alvarez-Sala R, Vazquez J, Ortega Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis. 2006; 10:409–414.

Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis. 2005; 9:507–513.

Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005; 365:318–326. http://dx.doi.org/10.1016/S0140-6736(05)70196-3

Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006; 61:158–163. http://dx.doi.org/10.1136/thx.2005.045963

Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis. 1995; 21:1238–1244. http://dx.doi.org/10.1093/clinids/21.5.1238

Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Bin Alwi Z, Naing NN. Multidrug resistant tuberculosis and risk factors associated with its development: a retrospective study. J Infect Dev Ctries. 2015; 9(10):1076–1085. http://dx.doi.org/10.3855/jidc.6162

Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010; 182:426–432. http://dx.doi.org/10.1164/rccm.200911-1768OC